Vyome Holdings, Inc.
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Vyome Holdings, Inc. (HIND) - Net Assets
Latest net assets as of September 2025: $3.92 Million USD
Based on the latest financial reports, Vyome Holdings, Inc. (HIND) has net assets worth $3.92 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.05 Million) and total liabilities ($3.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.92 Million |
| % of Total Assets | 55.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | -101.75% |
| 10-Year Change | -106.89% |
| Growth Volatility | 627.9 |
Vyome Holdings, Inc. - Net Assets Trend (2003–2024)
This chart illustrates how Vyome Holdings, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vyome Holdings, Inc. (2003–2024)
The table below shows the annual net assets of Vyome Holdings, Inc. from 2003 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-253.00K | -103.80% |
| 2023-12-31 | $6.66 Million | +82.00% |
| 2022-12-31 | $3.66 Million | -91.74% |
| 2021-12-31 | $44.33 Million | +206.00% |
| 2020-12-31 | $14.49 Million | -39.90% |
| 2019-12-31 | $24.11 Million | -23.86% |
| 2018-12-31 | $31.66 Million | -58.54% |
| 2017-12-31 | $76.37 Million | +2498.40% |
| 2016-12-31 | $2.94 Million | -19.98% |
| 2015-12-31 | $3.67 Million | -44.88% |
| 2014-12-31 | $6.66 Million | -54.60% |
| 2013-12-31 | $14.68 Million | +23.61% |
| 2012-12-31 | $11.88 Million | -40.75% |
| 2011-12-31 | $20.04 Million | -32.54% |
| 2010-12-31 | $29.71 Million | +432.29% |
| 2009-12-31 | $5.58 Million | -51.07% |
| 2008-12-31 | $11.41 Million | -74.81% |
| 2007-12-31 | $45.28 Million | +58.47% |
| 2006-12-31 | $28.57 Million | +1347.10% |
| 2005-12-31 | $1.97 Million | +394.71% |
| 2003-12-31 | $-670.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vyome Holdings, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64020000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.00K | % |
| Other Comprehensive Income | $-104.00K | % |
| Other Components | $642.53 Million | % |
| Total Equity | $-253.00K | 100.00% |
Vyome Holdings, Inc. Competitors by Market Cap
The table below lists competitors of Vyome Holdings, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SSH Group Ltd
AU:SSH
|
$3.27 Million |
|
Master Pack Group Bhd
KLSE:7029
|
$3.28 Million |
|
Tissue Repair Ltd
AU:TRP
|
$3.28 Million |
|
Hiper Global Ltd
TA:HIPR
|
$3.28 Million |
|
IQ-AI Limited
PINK:IQAIF
|
$3.27 Million |
|
Beston Global Food Company Ltd
AU:BFC
|
$3.27 Million |
|
Ind-Swift Limited
NSE:INDSWFTLTD
|
$3.27 Million |
|
Ausom Enterprise Limited
NSE:AUSOMENT
|
$3.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vyome Holdings, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,663,000 to -253,000, a change of -6,916,000 (-103.8%).
- Net loss of 7,130,000 reduced equity.
- Other comprehensive income decreased equity by 16,000.
- Other factors increased equity by 230,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.13 Million | -2818.18% |
| Other Comprehensive Income | $-16.00K | -6.32% |
| Other Changes | $230.00K | +90.91% |
| Total Change | $- | -103.80% |
Book Value vs Market Value Analysis
This analysis compares Vyome Holdings, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $-12219.59 | $2.12 | x |
| 2005-12-31 | $14716.79 | $2.12 | x |
| 2006-12-31 | $160139.95 | $2.12 | x |
| 2007-12-31 | $53708.36 | $2.12 | x |
| 2008-12-31 | $1964.58 | $2.12 | x |
| 2009-12-31 | $3253.70 | $2.12 | x |
| 2010-12-31 | $10232.18 | $2.12 | x |
| 2011-12-31 | $1924.11 | $2.12 | x |
| 2012-12-31 | $871.03 | $2.12 | x |
| 2014-12-31 | $867708.33 | $2.12 | x |
| 2015-12-31 | $478255.21 | $2.12 | x |
| 2017-12-31 | $9930689.21 | $2.12 | x |
| 2018-12-31 | $3618564.34 | $2.12 | x |
| 2019-12-31 | $1114001.85 | $2.12 | x |
| 2020-12-31 | $336930.23 | $2.12 | x |
| 2021-12-31 | $294187.13 | $2.12 | x |
| 2022-12-31 | $12508.54 | $2.12 | x |
| 2023-12-31 | $1622.35 | $2.12 | x |
| 2024-12-31 | $-12.27 | $2.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vyome Holdings, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -89.06%
- • Asset Turnover: 1.67x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-303.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.83 Million |
| 2005 | -567.99% | 0.00% | 0.00x | 5.85x | $-11.41 Million |
| 2006 | -61.91% | 0.00% | 0.00x | 1.26x | $-20.55 Million |
| 2007 | -63.11% | 0.00% | 0.00x | 1.30x | $-33.10 Million |
| 2008 | -332.08% | 0.00% | 0.00x | 2.48x | $-39.01 Million |
| 2009 | -572.10% | 0.00% | 0.00x | 2.91x | $-32.49 Million |
| 2010 | -58.39% | 0.00% | 0.00x | 1.30x | $-20.32 Million |
| 2011 | -129.72% | 0.00% | 0.00x | 1.62x | $-28.00 Million |
| 2012 | -197.56% | -7519.23% | 0.01x | 2.20x | $-24.65 Million |
| 2013 | -175.63% | 0.00% | 0.00x | 1.80x | $-27.25 Million |
| 2014 | -392.09% | 0.00% | 0.00x | 2.16x | $-26.80 Million |
| 2015 | -694.23% | -8732.53% | 0.03x | 3.15x | $-25.87 Million |
| 2016 | -794.86% | -2969.62% | 0.11x | 2.40x | $-23.65 Million |
| 2017 | -44.28% | -2627.34% | 0.01x | 1.16x | $-41.45 Million |
| 2018 | -256.30% | -13375.68% | 0.01x | 1.46x | $-84.32 Million |
| 2019 | -307.82% | -491.80% | 0.38x | 1.64x | $-76.62 Million |
| 2020 | -149.30% | -191.43% | 0.28x | 2.74x | $-23.08 Million |
| 2021 | -142.43% | -464.31% | 0.26x | 1.18x | $-67.58 Million |
| 2022 | -1262.33% | -411.16% | 1.00x | 3.08x | $-46.58 Million |
| 2023 | -170.90% | -131.22% | 0.81x | 1.61x | $-12.05 Million |
| 2024 | 0.00% | -89.06% | 1.67x | 0.00x | $-7.10 Million |
Industry Comparison
This section compares Vyome Holdings, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vyome Holdings, Inc. (HIND) | $3.92 Million | 0.00% | 0.80x | $3.27 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |